VRM
TAK icon

Vectors Research Management’s Takeda Pharmaceutical TAK Stock Holding History

Vectors Research Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-161
Closed -$3K – 479
2020
Q3 		$3K Hold
161
– – ﹤0.01% 373
2020
Q2 		$3K Sell
161
-10
-6% -$180 ﹤0.01% 380
2020
Q1 		$3K Hold
171
– – ﹤0.01% 405
2019
Q4 		$3K Buy
171
+161
+1,610% +$3.08K ﹤0.01% 475
2019
Q3 		$0 Sell
10
-3,941
-100% -$68.2K ﹤0.01% 489
2019
Q2 		$70K Hold
3,951
– – 0.04% 146
2019
Q1 		$80K Buy
+3,951
New +$79.5K 0.05% 139

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vectors Research Management's TAK Position: Q4 2020 in Review

Vectors Research Management sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 161 shares — an estimated $3K sold.

Vectors Research Management first reported a position in TAK in Q1 2019 and held it in 7 quarters. The position peaked at $80K in Q1 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

  • Vectors Research Management reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
  • Vectors Research Management sold 161 Takeda Pharmaceutical shares in Q4 2020, an estimated $3K.
  • Vectors Research Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 7 quarters.
  • Vectors Research Management's Takeda Pharmaceutical position peaked at $80K in Q1 2019.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Vectors Research Management's 13F filing for Q4 2020, filed 9 Feb 2021.